Small node-negative breast cancers may retain aggressive characteristics
Dr Tryfonidis speaks with ecancer at ESMO 2017 about the aggressive hallmarks identified in even small breast tumours. These findings come from a subgroup of MINDACT patients whose tumours were ranked as both low and high risk by MammaPrint and Adjuvant! Online, respectively - this discordance led to randomised treatment based on either risk. Based on 5 year distant metastasis-free survival, Dr Tryfonidis reports that patients who were treated with chemotherapy based on their MammaPrint risk score derived a survival benefit. More from ESMO 2017 : http://ecancer.org/conference/722-esmo-2017.php Ecancer website: http://ecancer.org/video/index.php Twitter: @ecancer Facebook: https://www.facebook.com/ecancer ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Dr Tryfonidis speaks with ecancer at ESMO 2017 about the aggressive hallmarks identified in even small breast tumours. These findings come from a subgroup of MINDACT patients whose tumours were ranked as both low and high risk by MammaPrint and Adjuvant! Online, respectively - this discordance led to randomised treatment based on either risk. Based on 5 year distant metastasis-free survival, Dr Tryfonidis reports that patients who were treated with chemotherapy based on their MammaPrint risk score derived a survival benefit. More from ESMO 2017 : http://ecancer.org/conference/722-esmo-2017.php Ecancer website: http://ecancer.org/video/index.php Twitter: @ecancer Facebook: https://www.facebook.com/ecancer ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.